TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18243822

Group type: EXPERIMENTAL
Intervention: SPE‐LC‐MS/MS
Number of subjects: 0

Group type: COMPARATOR
Intervention: SPE‐LC‐UV
Number of subjects: 0
Study: 16784008

Group type: EXPERIMENTAL
Intervention: Ze 339
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acrivastine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15021764

Group type: EXPERIMENTAL
Intervention: Nasal balloon inflation during descent
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no nasal balloon inflation)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Nasal balloon inflation after negative pressure
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Valsalva's maneuver
Number of subjects: 188
Study: 10697085

Group type: EXPERIMENTAL
Intervention: Arteriovenous (AV) impulse system
Number of subjects: 143

Group type: COMPARATOR
Intervention: Aspirin (325 mg)
Number of subjects: 143
Study: 9176645

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 0.8 mg b.i.d.
Number of subjects: 5
Study: 8222166

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (3 g/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: omega-6 fatty acids (placebo group)
Number of subjects: 20
Study: 2871333

Group type: EXPERIMENTAL
Intervention: sulindac
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: piroxicam
Number of subjects: 20

Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 20
Study: 31777160

Group type: EXPERIMENTAL
Intervention: LA emptying fraction (LAEF)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: LA expansion index (LAEi)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Higher left atrial volume index (LAVi)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Composite outcome of CV death or HF hospitalization
Number of subjects: 971
Study: 29846017

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Postoperative CRT
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Anastomotic leakage
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Impaired wound healing
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Any surgical complication (anastomotic leakage and/or wound healing disorder)
Number of subjects: 799
Study: 27227544

Group type: EXPERIMENTAL
Intervention: PDT-hemoporfin (532 nm laser irradiation at 96‐120 J/cm2 with hemoporfin 5mg/kg)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: PDT-hemoporfin
Number of subjects: 440

Group type: COMPARATOR
Intervention: PDT-placebo (irradiation with placebo)
Number of subjects: 440
Study: 23575211

Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU twice per week
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 22734374

Group type: EXPERIMENTAL
Intervention: Acupuncture before kinesitherapy (Group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Kinesitherapy before acupuncture (Group B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 29
Study: 20624511

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 18388017

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 16036503

Group type: EXPERIMENTAL
Intervention: Somatostatin (SST) 500 microg/h + 250 microg bolus
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pantoprazole (PAN) 8 mg/h + 80 mg bolus
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (PLA) normal saline
Number of subjects: 43
Study: 12585170

Group type: EXPERIMENTAL
Intervention: Zhongfeng No. II Oral Liquid (ZF II) plus western medicine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Western medicine alone (control group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Zhongfeng No. II Oral Liquid (ZF II) in animal model
Number of subjects: 160

Group type: COMPARATOR
Intervention: Normal saline (control group in animal model)
Number of subjects: 160
Study: 11096246

Group type: COMPARATOR
Intervention: Supine position (group 1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Prone position (group 2)
Number of subjects: 96
Study: 9312759

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (75 g) and i.v. glucagon test (1 mg)
Number of subjects: 100
Study: 10603808

Group type: EXPERIMENTAL
Intervention: Kangaroo method (K)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional method (T)
Number of subjects: 61
Study: 3827456

Group type: EXPERIMENTAL
Intervention: Deflazacort (30 mg/d for four weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prednisone (25 mg/d for four weeks)
Number of subjects: 10
Study: 30477836

Group type: EXPERIMENTAL
Intervention: Painting and handcrafting group art therapy (creative art therapy) for one month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 26768748

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise at high intensity and individual coaching for 3 months, followed by self-managed physical activity for 9 months.
Number of subjects: 35
Study: 25006770

Group type: EXPERIMENTAL
Intervention: Porous bovine bone mineral particles and non-cross-linked collagen membrane (test group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (uncovered alveolar sockets)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Test group (5 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (12 weeks)
Number of subjects: 28
Study: 22456105

Group type: EXPERIMENTAL
Intervention: Group A: Sexual intercourse after a 10-day abstinence period for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group B: Sexual intercourse twice a week for 3 months
Number of subjects: 120
Study: 20107105

Group type: EXPERIMENTAL
Intervention: EXE 10 microg b.i.d.
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: ROSI 4 mg b.i.d.
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: EXE 10 microg b.i.d. + ROSI 4 mg b.i.d.
Number of subjects: 137
Study: 18164498

Group type: EXPERIMENTAL
Intervention: Coronary cyclic flow variations (CCFV) group (n=14)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Non-CCFV group (n=117)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: CCFV group (n=14)
Number of subjects: 131
Study: 15800988

Group type: EXPERIMENTAL
Intervention: Device that applies kneading-like motion on the abdomen, used once daily for 20 min for 12 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Device that applies kneading-like motion on the abdomen
Number of subjects: 30
Study: 12777952

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate, administered once a day orally for 12 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group - Normotensive PMW receiving the same HRT
Number of subjects: 56
Study: 10392351

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) during induction
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) at the end of CNS-directed therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Post-chemotherapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Neutrophil count above 1 x 10(9)/l during continuation chemotherapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Neutrophil count less than 1 x 10(9)/l during continuation chemotherapy
Number of subjects: 14
Study: 8540453

Group type: EXPERIMENTAL
Intervention: Fish oil group (4 g/day of fish oil concentrate)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Entire patient group
Number of subjects: 610
Study: 1860286

Group type: EXPERIMENTAL
Intervention: Taurolin rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline rinse (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine rinse (Control)
Number of subjects: 0
Study: 28342045

Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (30 cm of water for 30 sec)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham maneuver (5 cm of water for 30 sec)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both maneuvers
Number of subjects: 21
Study: 25946099

Group type: EXPERIMENTAL
Intervention: Toric contact lens correction (ACUVUE MOIST for Astigmatism)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spherical contact lens correction (ACUVUE MOIST)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No correction
Number of subjects: 11
Study: 23348760

Group type: EXPERIMENTAL
Intervention: Patients with relapsing-remitting MS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 24
Study: 21327529

Group type: EXPERIMENTAL
Intervention: Electronic consult intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 19564670

Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure wound therapy (NPWT) at lower pressures (‐75 mm Hg or ‐100 mm Hg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous negative pressure wound therapy (NPWT) at higher pressure (‐125 mm Hg)
Number of subjects: 0
Study: 17520151

Group type: EXPERIMENTAL
Intervention: Topical application of keratin peptide treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of keratin-active formulation
Number of subjects: 0
Study: 14732296

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (final concentration 0.1, 1.0, and 10 mmol/L)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11683967

Group type: COMPARATOR
Intervention: Intravesical BCG therapy (21 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mitomycin C plus doxorubicin therapy (21 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subsequent instillation of the other intravesical therapy for non-responders
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both therapies (BCG and mitomycin C plus doxorubicin)
Number of subjects: 42
Study: 9843104

Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg daily for 5 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7857507

Group type: EXPERIMENTAL
Intervention: Hypericum extract LI 160 (300 mg three times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2672476

Group type: EXPERIMENTAL
Intervention: Invagination of the appendix stump
Number of subjects: 130

Group type: COMPARATOR
Intervention: Simple ligature of the appendix stump
Number of subjects: 130
Study: 356720

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3, 2 g/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium p-chlorphenoxyisobutyrate (Ca-CPIB, 2 g/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of CaCO3 and Ca-CPIB
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium p-chlorphenoxyisobutyrate (Ca-CPIB, either singly or in combination)
Number of subjects: 15
Study: 30012022

Group type: EXPERIMENTAL
Intervention: Head-mounted gaming home exercises (20 minutes per day for one month)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional vestibular rehabilitation
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Head-mounted gaming home exercises
Number of subjects: 47
Study: 24711350

Group type: EXPERIMENTAL
Intervention: AHEAD intervention (adapted from ASSIST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26318778

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 113
Study: 24195867

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 374

Group type: COMPARATOR
Intervention: Print intervention
Number of subjects: 374
Study: 21672267

Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category (CPC) score determined using the entire hospital record
Number of subjects: 131

Group type: COMPARATOR
Intervention: Cerebral Performance Category (CPC) score determined using the discharge summary alone
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category (CPC) score with survival to hospital discharge of 20%
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category (CPC) score with survival to hospital discharge of 30%
Number of subjects: 131
Study: 18644067

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 16488346

Group type: EXPERIMENTAL
Intervention: Artificial hydration (1L or more per day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Nonhydration (no artificial hydration)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Calculated fluid balance
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Artificial hydration
Number of subjects: 125
Study: 12779198

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide 8-hourly for 48 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: 5% saline (control) 8-hourly for 48 hours
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide
Number of subjects: 22
Study: 10882145

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FL) 40 mg single dose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FL) 60 mg per day for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PL) for 12 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FL) and Placebo (PL)
Number of subjects: 32
Study: 9386007

Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with extension torque load of 0.35 Nm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with extension torque load of 0.26 Nm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with extension torque load of 0.18 Nm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with flexion torque load of 0.09 Nm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation with flexion torque load of 0.18 Nm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Magnetic cortical stimulation without external load
Number of subjects: 9
Study: 8260298

Group type: EXPERIMENTAL
Intervention: Alfentanil 12.5 micrograms kg‐1 injected into the deltoid muscle (n = 30)
Number of subjects: 90
Study: 3517250

Group type: EXPERIMENTAL
Intervention: Lymphokine-activated killer (LAK) cells
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination therapy with LAK cells and IL-2
Number of subjects: 9
Study: 29908669

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study: 26527782

Group type: EXPERIMENTAL
Intervention: Imatinib for 3 years
Number of subjects: 400

Group type: COMPARATOR
Intervention: Imatinib for 1 year
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Imatinib for 3 years in patients with centrally confirmed GIST without macroscopic metastases
Number of subjects: 400

Group type: COMPARATOR
Intervention: Imatinib for 1 year in patients with centrally confirmed GIST without macroscopic metastases
Number of subjects: 400
Study: 27128609

Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Darexaban 60 mg with ketoconazole 400 mg once daily on Days 1-9
Number of subjects: 26
Study: 23791510

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20674510

Group type: EXPERIMENTAL
Intervention: Unidirectional knotless barbed suture
Number of subjects: 44

Group type: COMPARATOR
Intervention: Continuous suture with intracorporeal knots
Number of subjects: 44
Study: 19597409

Group type: EXPERIMENTAL
Intervention: Ketoprofen 10% spray gel (360 mg/die)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral ketoprofen (25 mg t.i.d.)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no pharmacological treatment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ketoprofen 10% spray gel
Number of subjects: 41
Study: 15917156

Group type: EXPERIMENTAL
Intervention: Applied relaxation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral estradiol treatment
Number of subjects: 30
Study: 14601367

Group type: EXPERIMENTAL
Intervention: Epoetin alpha as an adjuvant treatment to preoperative autologous blood donation (PAD) program (40,000 IU weekly for 21, 14, and 7 days before surgery)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Epoetin alpha alone (2 doses weekly for the same period)
Number of subjects: 75
Study: 10773049

Group type: EXPERIMENTAL
Intervention: Platelet concentrates (PCs) in plasma
Number of subjects: 21

Group type: COMPARATOR
Intervention: Platelet concentrates (PCs) in PAS‐2
Number of subjects: 21
Study: 8817981

Group type: EXPERIMENTAL
Intervention: Centrifugal left heart bypass with oxygenation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard left heart bypass
Number of subjects: 25
Study: 1332737

Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms/kg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Metoclopramide 2 mg/kg every 2 h for five doses plus dexamethasone 10 mg and diphenhydramine
Number of subjects: 151
Study: 4016522

Group type: EXPERIMENTAL
Intervention: Continuous intravenous morphine infusion
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intermittent intramuscular morphine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 75
Study: 30763176

Group type: EXPERIMENTAL
Intervention: Therapist-guided iCBT
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Self-managed iCBT
Number of subjects: 254

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 254
Study: 29390433

Group type: EXPERIMENTAL
Intervention: Pro‐kin system with additional conventional balance training for 20 minutes per session, 5 times a week, for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 40
Study: 26135348

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice for 1 week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (placebo) for 1 week
Number of subjects: 27
Study: 23749153

Group type: EXPERIMENTAL
Intervention: Half-molar sodium lactate (SL) infusion at 0.5 ml/kg/h for 48 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline solution (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Half-molar sodium lactate (SL) infusion
Number of subjects: 60
Study: 21685643

Group type: EXPERIMENTAL
Intervention: High-arousal virtual environment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-arousal virtual environment
Number of subjects: 60
Study: 20113610

Group type: EXPERIMENTAL
Intervention: Montessori education (two-hour Montessori pedagogical activities every day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 0
Study: 16427556

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5%) via ON-Q pain management system for 72 hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% NaCl (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5%) via ON-Q pain management system
Number of subjects: 70
Study: 14578367

Group type: EXPERIMENTAL
Intervention: Hypercapnic hypoxia (HH)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both conditions (HH and Normoxia)
Number of subjects: 13
Study: 11445478

Group type: EXPERIMENTAL
Intervention: Flaxseed-supplemented, fat-restricted diet (30 g/day flaxseed, 20% of kilocalories or less from fat)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Historic controls (matched by age, race, PSA level at diagnosis, and biopsy Gleason sum)
Number of subjects: 25
Study: 9502368

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 8062886

Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) at doses of 0.5, 1.25, 2.5, 5.0, or 10 micrograms/kg/d by subcutaneous injection for 21-day cycles
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) at doses of 5.0 micrograms/kg/d or higher
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3)
Number of subjects: 21
Study: 3064773

Group type: EXPERIMENTAL
Intervention: Breast-preserving therapy
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 847

Group type: COMPARATOR
Intervention: Non-randomized group (breast-preserving therapy)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Non-randomized group (mastectomy)
Number of subjects: 847
Study: 30728053

Group type: EXPERIMENTAL
Intervention: ACS QUIK toolkit intervention
Number of subjects: 21374
Study: 29146650

Group type: EXPERIMENTAL
Intervention: Iron syrup (12.5 mg elemental iron)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powders (MMPs including 12.5 mg elemental iron)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Placebo MNPs
Number of subjects: 3300
Study: 26686508

Group type: EXPERIMENTAL
Intervention: DTP-HB-Hib vaccine (3 doses with 4-week intervals)
Number of subjects: 600
Study: 23582676

Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional testing
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ILR
Number of subjects: 78